103 related articles for article (PubMed ID: 2402017)
1. Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity.
Kelner MJ; McMorris TC; Taetle R
J Natl Cancer Inst; 1990 Oct; 82(19):1562-5. PubMed ID: 2402017
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of illudins as anticancer agents.
Kelner MJ; McMorris TC; Beck WT; Zamora JM; Taetle R
Cancer Res; 1987 Jun; 47(12):3186-9. PubMed ID: 3472654
[TBL] [Abstract][Full Text] [Related]
3. On the mechanism of toxicity of illudins: the role of glutathione.
McMorris TC; Kelner MJ; Wang W; Moon S; Taetle R
Chem Res Toxicol; 1990; 3(6):574-9. PubMed ID: 2103329
[TBL] [Abstract][Full Text] [Related]
4. NADPH alkenal/one oxidoreductase activity determines sensitivity of cancer cells to the chemotherapeutic alkylating agent irofulven.
Dick RA; Yu X; Kensler TW
Clin Cancer Res; 2004 Feb; 10(4):1492-9. PubMed ID: 14977853
[TBL] [Abstract][Full Text] [Related]
5. Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells. Unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents.
Kelner MJ; McMorris TC; Estes L; Rutherford M; Montoya M; Goldstein J; Samson K; Starr R; Taetle R
Biochem Pharmacol; 1994 Jul; 48(2):403-9. PubMed ID: 8053936
[TBL] [Abstract][Full Text] [Related]
6. Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells.
Kelner MJ; McMorris TC; Montoya MA; Estes L; Rutherford M; Samson KM; Taetle R
Cancer Chemother Pharmacol; 1997; 40(1):65-71. PubMed ID: 9137532
[TBL] [Abstract][Full Text] [Related]
7. Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan.
Kelner MJ; McMorris TC; Estes L; Samson KM; Trani NA; MacDonald JR
Leukemia; 2000 Jan; 14(1):136-41. PubMed ID: 10637489
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship studies of illudins: analogues possessing a spiro-cyclobutane ring.
McMorris TC; Cong Q; Kelner MJ
J Org Chem; 2003 Dec; 68(25):9648-53. PubMed ID: 14656090
[TBL] [Abstract][Full Text] [Related]
9. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells.
Nagasawa K; Natazuka T; Chihara K; Kitazawa F; Tsumura A; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Cancer Chemother Pharmacol; 1996; 37(4):297-304. PubMed ID: 8548874
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells.
Kelner MJ; McMorris TC; Estes L; Starr RJ; Rutherford M; Montoya M; Samson KM; Taetle R
Cancer Res; 1995 Nov; 55(21):4936-40. PubMed ID: 7585533
[TBL] [Abstract][Full Text] [Related]
11. Characterization of acylfulvene histiospecific toxicity in human tumor cell lines.
Kelner MJ; McMorris TC; Montoya MA; Estes L; Uglik SF; Rutherford M; Samson KM; Bagnell RD; Taetle R
Cancer Chemother Pharmacol; 1998; 41(3):237-42. PubMed ID: 9443641
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity studies of urea, carbamate, and sulfonamide derivatives of acylfulvene.
McMorris TC; Chimmani R; Alisala K; Staake MD; Banda G; Kelner MJ
J Med Chem; 2010 Feb; 53(3):1109-16. PubMed ID: 20067264
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of antitumor acylfulvene by rat liver cytosol.
McMorris TC; Elayadi AN; Yu J; Kelner MJ
Biochem Pharmacol; 1999 Jan; 57(1):83-8. PubMed ID: 9920288
[TBL] [Abstract][Full Text] [Related]
14. Identification of illudins in Omphalotus nidiformis and Omphalotus olivascens var. indigo by column liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry.
Kirchmair M; Pöder R; Huber CG
J Chromatogr A; 1999 Feb; 832(1-2):247-52. PubMed ID: 10070774
[TBL] [Abstract][Full Text] [Related]
15. (Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties.
McMorris TC; Kelner MJ; Wang W; Yu J; Estes LA; Taetle R
J Nat Prod; 1996 Sep; 59(9):896-9. PubMed ID: 8864242
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo studies on the anticancer activity of dehydroilludin M.
Kelner MJ; McMorris TC; Taetle R
Anticancer Res; 1995; 15(3):873-8. PubMed ID: 7645974
[TBL] [Abstract][Full Text] [Related]
17. Quantification of acylfulvene- and illudin S-DNA adducts in cells with variable bioactivation capacities.
Pietsch KE; van Midwoud PM; Villalta PW; Sturla SJ
Chem Res Toxicol; 2013 Jan; 26(1):146-55. PubMed ID: 23227857
[TBL] [Abstract][Full Text] [Related]
18. Discovery and characterisation of a broderol-like illudin, omphaderol in the mycelial extracts of Omphalotus mexicanus (Omphalotaceae) using UPLC-QTOF-MS and NMR spectroscopy.
Eckhardt P; Reinecke S; Opatz T; Stadler M; Sandargo B
Phytochem Anal; 2024 Apr; 35(3):469-475. PubMed ID: 37923375
[TBL] [Abstract][Full Text] [Related]
19. Irofulven (MGI Pharma).
Baekelandt M
Curr Opin Investig Drugs; 2002 Oct; 3(10):1517-26. PubMed ID: 12431030
[TBL] [Abstract][Full Text] [Related]
20. A Chemical Proteomic Analysis of Illudin-Interacting Proteins.
Le P; Nodwell MB; Eirich J; Sieber SA
Chemistry; 2019 Sep; 25(54):12644-12651. PubMed ID: 31310394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
